{
  "id": 15949052,
  "title": "Jefferies raises Disc Medicine stock price target on drug opportunity",
  "url": "https://urgent.news/2026/10/21/jefferies-raises-disc-medicine-stock-price-target-on-drug-opportunity",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-21T20:48:42.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/jefferies-raises-disc-medicine-stock-price-target-on-drug-opportunity-93CH-4964114"
  },
  "original_language": "en",
  "account": "Jefferies has increased its price target for Disc Medicine shares (NASDAQ:IRON) from $128 to $149, while maintaining a \"Buy\" rating. The company's stock has experienced a significant 42.6% increase over the past week due to positive clinical results. The investment firm highlighted the Phase 3 topline results for bitopertin, which is touted as the first disease-modifying drug in its medical field. Following the New Drug Application resubmission by end of 2026, Jefferies anticipates approval by mid-2027.\n\nDisc Medicine's market capitalization is valued at $2.93 billion, and the firm estimates a patient pool of roughly 6,000 to 14,000. This patient base could potentially generate a commercial opportunity worth $1 billion to $2 billion. Jefferies anticipates presenting data and regulatory updates for its myelofibrosis anemia program and longer-term follow-up data for its polycythemia vera program before year-end 2026, possibly at the American Society of Hematology meeting.\n\nRecent analyst updates have also reflected positively on Disc Medicine. BMO Capital increased its price target to $120 from $100, keeping an \"Outperform\" rating, thanks to the Phase 3 APOLLO trial results. Cantor Fitzgerald raised its price target to $170 from $125, also commending the Phase 3 results for bitopertin in the treatment of severe photosensitivity conditions. Wells Fargo adjusted its price target to $124 from $86, emphasizing the competitive aspects of the company's data in the EPP/XLP index. Truist Securities raised its target to $115 from $83, driven by increased confidence in the regulatory outlook for bitopertin following the APOLLO trial results. Lastly, H.C. Wainwright maintained its \"Buy\" rating with a $120 price target, following the promising Phase 2 RESTORE-PV trial outcomes. These developments demonstrate strong analyst backing, driven by Disc Medicine's recent clinical trial results.",
  "summary": null,
  "key_points": [
    "Jefferies raises Disc Medicine's stock price target from $128 to $149",
    "Positive Phase 3 clinical results for bitopertin drive 42.6% stock increase",
    "Anticipated NDA resubmission by end of 2026 with potential $1B-$2B commercial opportunity"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}